EODData

OTCBB, HBPCF: Helix Biopharma Corp

20 Mar 2026
LAST:

1.730

CHANGE:
 0.00
OPEN:
1.730
HIGH:
1.730
ASK:
0.000
VOLUME:
100
CHG(%):
0.22
PREV:
1.734
LOW:
1.730
BID:
0.000
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume

PROFILE

Name:Helix Biopharma Corp
About:Helix BioPharma Corp. operates as an immune-oncology company in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
Sector:Healthcare
Industry:Biotechnology
Address:1055 West Georgia Street, Vancouver, BC, Canada, V6E 3P3
Website:https://www.helixbiopharma.com
CUSIP:422910109
CIK:0001305591
ISIN:US4229101096
FIGI:BBG000K9PGP7

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

TECHNICAL INDICATORS

MA5:1.0269.3%
Week High:1.730.0%
Week Low:1.730.0%

RECENT SPLITS

Date Ratio
16 Aug 20241-5